SCHEMBL5437771

SCHEMBL5437771

O=C(Nc1nc2ccc(C=Cc3cnc(Nc4ccc(S(=O)(=O)N5CCNCC5)cc4)nc3)cc2s1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.49
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
MAPT P10636 7/20 0.46
TP53 P04637 4/20 0.46
RXFP1 Q9HBX9 2/20 0.44
TRPV4 Q9HBA0 1/20 0.44
IKBKB O14920 1/20 0.43
CHUK O15111 1/20 0.43
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 4/20 0.43
USP2 O75604 3/20 0.43
HTT P42858 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 2/20 0.43
POLB P06746 2/20 0.43
CLK1 P49759 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437768 1.00 LMNA (0.49) LMNAMEN1KMT2AMAPTTP53
SCHEMBL14490596 0.93 LMNA (0.56) LMNAMEN1KMT2AMAPTTP53
SCHEMBL14538312 0.91 RXFP1 (0.51) LMNAMEN1KMT2AMAPTTP53
SCHEMBL5450760 0.89 PDE4B (0.41) LMNAMEN1KMT2AMAPTRXFP1
SCHEMBL5450750 0.89 PDE4B (0.41) LMNAMEN1KMT2AMAPTRXFP1
SCHEMBL5443986 0.80 LMNA (0.49) LMNAMEN1KMT2AMAPTTP53
SCHEMBL5443996 0.80 LMNA (0.49) LMNAMEN1KMT2AMAPTTP53
SCHEMBL14490150 0.79 ALDH1A1 (0.48) MAPTIKBKBCHUKALDH1A1HPGD
Hydrochloric Acid SCHEMBL5437586 0.78 ALDH1A1 (0.48) MAPTIKBKBCHUKALDH1A1HPGD
Hydrochloric Acid SCHEMBL5437574 0.78 ALDH1A1 (0.48) MAPTIKBKBCHUKALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR LMNA 1837/4885MEN1 1745/4885KMT2A 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.